Record does not exist anymore: Environmental Information Data Centre . The record with identifier content 10.25504/FAIRsharing.9raft1 was invalid.

The UK Solar System Data Centre (UKSSDC) is the Natural Environment Research Council's (NERC) Designated Data Centre for the Solar terrestrial physics and chemistry. It provides a central archive and data centre facility for Solar System science in the UK. The UKSSDC supports data archives for the whole UK solar system community encompassing solar, inter-planetary, magnetospheric, ionospheric and geomagnetic science. The UKSSDC is part of RAL Space based at the STFC run Rutherford Appleton Laboratory in Oxfordshire.

The COVID-19 Research Repository has been developed by Public Health Scotland (PHS) with an aim to bring together and provide access to Scottish COVID-19 research on a single shared platform in order to promote Scottish research to an international audience. The main objectives of the repository are to: -make research easier to find -raise awareness of Scottish research -track, understand and report on the impact of this work - reduce duplication of effort -encourage a collaborative, cross-sectoral approach to COVID-19 research in Scotland -provide full-text open access to research wherever possible -ensure permanent preservation of PHS research

modMine is an integrated web resource of data and tools to browse and search modENCODE data and experimental details, download results and access the GBrowse genome browser.

Ensembl Plants holds the genomes of plants of significant interest. These range from those of agricultural importance, those which support primary research and of environmental interest. Ensembl Plants datasets are constructed in a direct collaboration with the Gramene resource. The resource holds the genomes of wheat, rice, corn and mouse ear cress amongst others.

The Clinical Trials Information System (CTIS) is the online system for the regulatory submission, authorisation and supervision of clinical trials in the European Union and the European Economic Area. From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS). CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data. This follows a one-year transition, during which sponsors could choose whether to apply for a new clinical trial in the EU/EEA in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022.

This is a portal to the consensus yeast metabolic network as reconstructed from the genome sequence and literature. It is a highly annotated metabolic map of Saccharomyces cerevisiae S288c that is periodically updated by a team of collaborators from various research groups.

CAPACITY-COVID is a registry of patients with COVID-19, their history of cardiovascular disease and the occurrence of cardiovascular complications in COVID-19 patients. CAPACITY uses an extension of the CRF released by the ISARIC and WHO in response to the emerging outbreak of COVID-19.

The Rfam database is a collection of RNA families, each represented by multiple sequence alignments, consensus secondary structures and covariance models (CMs). The families in Rfam break down into three broad functional classes: non-coding RNA genes, structured cis-regulatory elements and self-splicing RNAs. Typically these functional RNAs often have a conserved secondary structure which may be better preserved than the RNA sequence.

Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.